S&P 500   4,321.33 (+0.03%)
DOW   33,907.22 (-0.17%)
QQQ   357.65 (-0.07%)
AAPL   174.83 (+0.02%)
MSFT   317.22 (+0.07%)
META   296.11 (-0.99%)
GOOGL   129.98 (-0.21%)
AMZN   129.86 (+0.57%)
TSLA   240.19 (-1.92%)
NVDA   416.05 (-0.01%)
NIO   8.08 (-5.28%)
BABA   86.21 (-2.37%)
AMD   96.24 (+0.04%)
T   14.93 (-1.26%)
F   12.38 (-0.40%)
MU   67.97 (-1.32%)
CGC   0.88 (+4.41%)
GE   111.07 (-0.16%)
DIS   81.01 (-0.30%)
AMC   7.64 (+0.26%)
PFE   32.46 (-0.70%)
PYPL   58.23 (+0.60%)
NFLX   384.47 (+1.23%)
S&P 500   4,321.33 (+0.03%)
DOW   33,907.22 (-0.17%)
QQQ   357.65 (-0.07%)
AAPL   174.83 (+0.02%)
MSFT   317.22 (+0.07%)
META   296.11 (-0.99%)
GOOGL   129.98 (-0.21%)
AMZN   129.86 (+0.57%)
TSLA   240.19 (-1.92%)
NVDA   416.05 (-0.01%)
NIO   8.08 (-5.28%)
BABA   86.21 (-2.37%)
AMD   96.24 (+0.04%)
T   14.93 (-1.26%)
F   12.38 (-0.40%)
MU   67.97 (-1.32%)
CGC   0.88 (+4.41%)
GE   111.07 (-0.16%)
DIS   81.01 (-0.30%)
AMC   7.64 (+0.26%)
PFE   32.46 (-0.70%)
PYPL   58.23 (+0.60%)
NFLX   384.47 (+1.23%)
S&P 500   4,321.33 (+0.03%)
DOW   33,907.22 (-0.17%)
QQQ   357.65 (-0.07%)
AAPL   174.83 (+0.02%)
MSFT   317.22 (+0.07%)
META   296.11 (-0.99%)
GOOGL   129.98 (-0.21%)
AMZN   129.86 (+0.57%)
TSLA   240.19 (-1.92%)
NVDA   416.05 (-0.01%)
NIO   8.08 (-5.28%)
BABA   86.21 (-2.37%)
AMD   96.24 (+0.04%)
T   14.93 (-1.26%)
F   12.38 (-0.40%)
MU   67.97 (-1.32%)
CGC   0.88 (+4.41%)
GE   111.07 (-0.16%)
DIS   81.01 (-0.30%)
AMC   7.64 (+0.26%)
PFE   32.46 (-0.70%)
PYPL   58.23 (+0.60%)
NFLX   384.47 (+1.23%)
S&P 500   4,321.33 (+0.03%)
DOW   33,907.22 (-0.17%)
QQQ   357.65 (-0.07%)
AAPL   174.83 (+0.02%)
MSFT   317.22 (+0.07%)
META   296.11 (-0.99%)
GOOGL   129.98 (-0.21%)
AMZN   129.86 (+0.57%)
TSLA   240.19 (-1.92%)
NVDA   416.05 (-0.01%)
NIO   8.08 (-5.28%)
BABA   86.21 (-2.37%)
AMD   96.24 (+0.04%)
T   14.93 (-1.26%)
F   12.38 (-0.40%)
MU   67.97 (-1.32%)
CGC   0.88 (+4.41%)
GE   111.07 (-0.16%)
DIS   81.01 (-0.30%)
AMC   7.64 (+0.26%)
PFE   32.46 (-0.70%)
PYPL   58.23 (+0.60%)
NFLX   384.47 (+1.23%)
NASDAQ:TRVN

Trevena (TRVN) Competitors

$0.65
-0.02 (-2.75%)
(As of 09:40 AM ET)
Compare
Today's Range
$0.64
$0.66
50-Day Range
$0.66
$1.02
52-Week Range
$0.54
$5.13
Volume
33,265 shs
Average Volume
1.25 million shs
Market Capitalization
$8.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

TRVN vs. APGN, CMRA, CVKD, VRPX, CYCN, CANF, SBFM, BWV, ITRM, and GTBP

Should you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Apexigen (APGN), Comera Life Sciences (CMRA), Cadrenal Therapeutics (CVKD), Virpax Pharmaceuticals (VRPX), Cyclerion Therapeutics (CYCN), Can-Fite BioPharma (CANF), Sunshine Biopharma (SBFM), Blue Water Biotech (BWV), Iterum Therapeutics (ITRM), and GT Biopharma (GTBP). These companies are all part of the "pharmaceutical preparations" industry.

Trevena vs.

Apexigen (NASDAQ:APGN) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking.

Trevena received 610 more outperform votes than Apexigen when rated by MarketBeat users. However, 80.00% of users gave Apexigen an outperform vote while only 74.15% of users gave Trevena an outperform vote.

CompanyUnderperformOutperform
ApexigenOutperform Votes
4
80.00%
Underperform Votes
1
20.00%
TrevenaOutperform Votes
614
74.15%
Underperform Votes
214
25.85%

Apexigen currently has a consensus price target of $11.50, suggesting a potential upside of 2,886.24%. Trevena has a consensus price target of $5.50, suggesting a potential upside of 727.69%. Given Trevena's higher possible upside, research analysts clearly believe Apexigen is more favorable than Trevena.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apexigen
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Trevena
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Apexigen has a beta of 3.6, meaning that its share price is 260% more volatile than the S&P 500. Comparatively, Trevena has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500.

Apexigen has higher earnings, but lower revenue than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ApexigenN/AN/A-$32.07MN/AN/A
Trevena$570K15.98-$53.67M-$4.48-0.15

Apexigen's return on equity of -265.73% beat Trevena's return on equity.

Company Net Margins Return on Equity Return on Assets
ApexigenN/A -614.82% -133.30%
Trevena N/A -265.73%-86.25%

In the previous week, Trevena's average media sentiment score of 0.00 equaled Apexigen'saverage media sentiment score.

Company Overall Sentiment
Apexigen Neutral
Trevena Neutral

13.6% of Apexigen shares are owned by institutional investors. Comparatively, 5.0% of Trevena shares are owned by institutional investors. 19.2% of Apexigen shares are owned by insiders. Comparatively, 3.3% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Apexigen beats Trevena on 6 of the 11 factors compared between the two stocks.


Get Trevena News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRVN vs. The Competition

MetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$9.11M$5.72B$4.33B$6.25B
Dividend YieldN/A2.65%5.81%6.53%
P/E Ratio-0.157.07139.0613.64
Price / Sales15.98151.722,934.2954.71
Price / CashN/A21.5690.04101.36
Price / Book0.304.003.834.78
Net Income-$53.67M$197.94M$121.81M$185.28M
7 Day Performance-8.97%-0.97%110.50%3.51%
1 Month Performance-26.17%-4.35%113.70%8.58%
1 Year Performance-83.89%5.38%129.92%4.85%

Trevena Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APGN
Apexigen
0 of 5 stars
$0.39
flat
$11.50
+2,887.0%
N/A$9.57MN/A0.0011
CMRA
Comera Life Sciences
0 of 5 stars
$0.35
flat
N/A-83.4%$9.51M$630,000.00-0.5912Gap Down
CVKD
Cadrenal Therapeutics
0 of 5 stars
$0.74
+2.8%
N/AN/A$9.64MN/A0.003Positive News
VRPX
Virpax Pharmaceuticals
0 of 5 stars
$0.83
+7.8%
N/A-33.0%$9.72MN/A-0.637High Trading Volume
CYCN
Cyclerion Therapeutics
0 of 5 stars
$3.75
-3.8%
N/A-78.0%$9.40M$1.63M-0.2916Positive News
Gap Down
CANF
Can-Fite BioPharma
1.375 of 5 stars
$2.65
flat
$23.00
+769.6%
+239.9%$9.36M$810,000.00-0.868
SBFM
Sunshine Biopharma
2.2634 of 5 stars
$0.38
flat
$2.60
+584.2%
-58.1%$9.79M$4.35M-0.2346Positive News
Gap Up
BWV
Blue Water Biotech
1.9794 of 5 stars
$0.61
-1.6%
N/AN/A$9.86MN/A-0.6312News Coverage
ITRM
Iterum Therapeutics
0 of 5 stars
$0.76
flat
N/A-54.7%$9.90MN/A-0.1714Positive News
GTBP
GT Biopharma
1.7778 of 5 stars
$0.25
flat
$3.50
+1,299.4%
-87.0%$9.96MN/A-0.542Gap Up

Related Companies and Tools

This page (NASDAQ:TRVN) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -